Philippe Halfon

Genoscience Pharma is a French clinical-stage biotechnology company that develops novel lysosomotropic therapeutics to establish a new standard of care against cancer, autoimmune, and infectious diseases. The private company is based in Marseille, France and was founded in 2001 by Philippe Halfon. Its lead candidate, GNS561, is a phase 2 ready drug candidate that tackles cancer cells through autophagy modulation. Genoscience Pharma is also entering a phase 2 trial with GNS561.

Genoscience Pharma is a French clinical-stage biotechnology company that develops novel lysosomotropic therapeutics to establish a new standard of care against cancer, autoimmune, and infectious diseases. The private company is based in Marseille, France and was founded in 2001 by Philippe Halfon. Its lead candidate, GNS561, is a phase 2 ready drug candidate that tackles cancer cells through autophagy modulation. Genoscience Pharma is also entering a phase 2 trial with GNS561.

Genoscience Pharma is a French clinical-stage biotechnology company that develops novel lysosomotropic therapeutics to establish a new standard of care against cancer, autoimmune, and infectious diseases. The private company is based in Marseille, France and was founded in 2001 by Philippe Halfon. Its lead candidate, GNS561, is a phase 2 ready drug candidate that tackles cancer cells through autophagy modulation. Genoscience Pharma is also entering a phase 2 trial with GNS561.